---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-061121"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2023-11-08T23:59:59+00:00"
generated_at: "2026-06-08T09:48:27.290356+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio Q3 net loss $49.9M ($1.16/share); goodwill impairment of $19.5M

## Summary
- Revenue not reported; R&D expenses $26.2M vs $16.6M YoY; G&A $6.6M vs $6.4M.
- Cash $183.3M at Sept 30 2023, down from $257.7M at Dec 31 2022; runway into H1 2025.
- Initiated ADI-001 EXPAND cohort in post-CAR T LBCL; MCL enrollment continues.
- Prioritizing ADI-270 for solid tumors; IND filing expected H1 2024; paused ADI-925.
- Goodwill fully impaired by $19.5M following impairment test.

## SEC filing metadata
- accession: 0000950170-23-061121
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2023-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000095017023061121/0000950170-23-061121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000095017023061121/acet-20231108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-061121
- JSON: https://secwatch.observer/filing/0000950170-23-061121.json
- Plain text: https://secwatch.observer/filing/0000950170-23-061121.txt

## Key facts
- Earnings Releases
  Adicet Bio, Inc. reported the third quarter ended September 30, 2023 results: net income $49.9 million, EPS $1.16 per basic and diluted share.
  - Period: the third quarter ended September 30, 2023
  - Net income: $49.9 million
  - EPS: $1.16 per basic and diluted share
  - Result: reported results
  source text: Net loss for the three months ended September 30, 2023 was $49.9 million, or a net loss of $1.16 per basic and diluted share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720580/000095017023061121/0000950170-23-061121-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.